U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

The FDA Drug Shortage database is currently experiencing technical difficulties and some of the information contained in the database may not reflect the current supply status.

Start Over | Back to Previous Screen

Sodium Bicarbonate Injection
Status: Currently in Shortage
»Date first posted: 03/01/2017
»Therapeutic Categories: Endocrinology/Metabolism; Gastroenterology; Pediatric

Expand all

Amphastar Pharmaceuticals, Inc./IMS (Reverified 08/12/2022)

Company Contact Information:
800-423-4136

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Sodium Bicarbonate Inj. USP, 8.4%, 50mL Luer-Jet Prefilled Syringe, (NDC 0548-3352-00), (new NDC 76329-3352-1) Backorder due to the increase in demands Demand increase for the drug

Exela Pharma Sciences, LLC (Revised 01/31/2022)

Company Contact Information:
828-758-5474 ext. 154

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
8.4%, 50mL (NDC 51754-5001-05) Available Demand increase for the drug
10 mEq/10 mL (NDC 2551754-5011-04) Currently on backorder
5 mEq/10 mL, 4.2%, (NDC 51754-5012-04) On backorder

Fresenius Kabi USA, LLC (Reverified 08/12/2022)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
4.2% Single dose vial, 2.5 mEq per 5 mL (0.5 mEq per mL) (42 mg per mL)(NDC 63323-083-05) Available Demand increase for the drug
8.4% Single dose vial, 50 mEq per 50 mL (1 mEq per mL) (84 mg per mL)(NDC 63323-089-50) Available Demand increase for the drug

Hospira, Inc. (Revised 07/01/2022)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Neut (Sodium Bicarbonate Additive Solution); 200 mg/5 mL (4%); Single Dose Glass Fliptop Vial (NDC 0409-6609-02) Discontinued Discontinuation of the manufacture of the drug
Infant 5 mEq/10 mL (0.5 mEq/mL) ABBOJECT® Glass Syringe (4.2% Concentration) (NDC 0409-5534-14) (old NDC 0409-5534-34) Available

Pfizer Customer Letter dated March 4, 2022.

Other
50 mEq/50 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-6637-14) (old NDC 0409-6637-34) Next Delivery: June 2022; Estimated Recovery: January 2023

Pfizer Customer Letter dated March 4, 2022.

Demand increase for the drug
2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial (4.2% Concentration) (NDC 0409-5555-02) Available Other
2.5 mEq/5 mL (0.5 mEq/mL) Fliptop Vial Novaplus® (4.2% Concentration) (NDC 0409-5555-01) Available Other
44.6 mEq/50 mL (0.9 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe (7.5% concentration) (NDC 0409-4916-14) (old NDC 0409-4916-34) Available

Pfizer Customer Letter dated March 4, 2022.

Other
50 mEq/50 mL (1 mEq/mL) Single Dose Glass Fliptop Vial (8.4% concentration) (NDC 0409-6625-14) (old NDC 0409-6625-02) Available

Dear Customer Letter: Availability Update for Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL)

Other
50 mEq/50 mL (1 mEq/mL) Single Dose Vial Novaplus® (8.4% concentration) (NDC 0409-6625-35) Available Other
Pediatric 10 mEq/10 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe (8.4% Concentration) (NDC 0409-4900-14) (old NDC 0409-4900-34) Next Delivery: June 2022; Estimated Recovery: January 2023

Pfizer Customer Letter dated March 4, 2022.

Demand increase for the drug
Back to Top